Definitive Healthcare (DH) Q2 2026 Earnings Call
Definitive Healthcare (DH) reported Q2 FY26 revenue of $55.2 million, down 9% year over year, with adjusted EBITDA of $14.6 million and net dollar retention improving for a second straight quarter. Subscription revenue fell 9% to $52.8 million. Full-year guidance: revenue $220-$222 million and adjusted EBITDA $57-$59 million; Q3 revenue $54-$55 million.
How this was made
The 30-second read
Why it matters
Traders can reprice the stock based on the combination of (1) profitability/margins beating guidance, (2) full-year revenue still expected to decline, (3) Q3 revenue and EBITDA guidance ranges, and (4) RPO down 18% tied to a shift toward single-year contracts.
Market read
A guidance update with detailed operating metrics (EBITDA margin, retention, RPO, and Turbo rollout) creates a tradable setup for earnings-follow-through and guidance-sensitive positioning.
What to watch
Turbo GA targeting end-of-year and integration acceleration may improve retention later, but the article also flags slower life sciences response and lighter traditional analytics bookings that could persist into Q3.
Background
The article summarizes Definitive Healthcare’s Q2 FY 2026 earnings call, including KPIs, segment performance, and updated guidance.
Ticker impact
Definitive Healthcare reported Q2 results and raised full-year adjusted EBITDA guidance, with Turbo AI platform and RPO trends driving the outlook.
Near-term bias modestly positive on guidance and margin, tempered by segment drag and RPO decline.
The article provides multiple decision-relevant datapoints: Q2 profitability/margins above guidance, full-year revenue and EBITDA ranges, Q3 revenue/EBITDA guidance, and RPO down 18% with a shift to single-year deals. Offsetting risks include slower life sciences response and underperforming professional services bookings.
Market effects
Signals continued demand for healthcare data and AI-enabled intelligence, while contract-duration shifts (single-year deals) may pressure visibility across analytics vendors.
No specific regional impact disclosed.
No explicit global expansion or international regulatory drivers mentioned.
Counterpoint
The raised adjusted EBITDA guidance could be more expense-driven than demand-driven, while RPO decline and life sciences drag suggest revenue quality risk ahead.
Key entities
- companyDefinitive Healthcare Corp.
Reported Q2 results, discussed Turbo AI platform rollout, and updated full-year and Q3 guidance.
- executiveKevin Coop
CEO who discussed life sciences response timing and Turbo’s transition toward agentic AI.
- executiveCasey Heller
CFO who cited professional services underperformance and guided full-year profitability/EBITDA.
